BioPharmSignal logoBioPharmSignal

Biotech News

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Biomea Fusion (BMEA)Biomea FusionClinical readout

Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027 COVALENT-212 Phase II enrollment T2D patients who are not achieving

Related news

BMEABiomea Fusion2026-10-13 20:08 EST

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

IMCRImmunocore Holdings plc2026-10-15 11:00 EST

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

SNDXSyndax Pharmaceuticals2026-10-12 20:01 EST

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ARGXArgenx2026-10-08 05:00 EST

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

IMCRImmunocore Holdings plc2026-09-14 11:00 EST

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

View all latest news

Biomea Fusion

Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and...

Recent company news

BMEABiomea Fusion2026-10-13 20:08 EST

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-22 20:05 EST

Biomea Fusion Announces Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

Stock data

Close
0.59 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States